Ozempic copies restricted after US judge denies injunction
April 24 (Reuters) - A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's (NOVOb.CO), opens new tab popular diabetes and weight-loss drugs Ozempic and Wegovy while a legal challenge over drug shortages unfolds, court records show.
The decision came in response to a February lawsuit from a compounding industry group against the U.S. Food and Drug Administration's decision that there was no longer a shortage of the medicines' active ingredient, semaglutide.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Compounders had been allowed to produce hundreds of thousands of doses of copies of Novo's obesity and diabetes drugs only while the FDA said they were in short supply. Many of these are sold by large telehealth companies like Hims & Hers.
U.S. District Judge Mark Pittman in Texas denied compounders' bid for a preliminary injunction, according to the court docket. Pittman filed his legal reasoning under seal, but by denying the injunction request, a May timeline set by the FDA for when large U.S. compounders will have to exit the market remains in place.
It also follows a decision the judge made earlier this year refusing to allow compounding pharmacies to keep making copies of Eli Lilly's (LLY.N), opens new tab weight-loss and diabetes drugs Zepbound and Mounjaro.
The FDA and Novo Nordisk did not immediately respond to requests for comment.
Lee Rosebush, chairman of lead plaintiff Outsourcing Facilities Association, told Reuters that his organization had presented evidence of an ongoing semaglutide shortage that was obtained after the lawsuit was filed. However, Rosebush said the judge declined to consider it, finding that it was filed late.
The FDA had said it would not take any enforcement action against compounders before the court ruled.
The regulator has given larger so-called outsourcing facilities, which make compounded drugs in bulk and are regulated by the agency, until May 22. Smaller compounding pharmacies, which make drugs to fill prescriptions for individual patients and are primarily overseen by U.S. states, must immediately cease making copies of semaglutide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
2 hours ago
- Reuters
South African rand shrugs off weak manufacturing data
JOHANNESBURG, June 10 (Reuters) - The South African rand strengthened on Tuesday despite a sharp contraction in local manufacturing output, as investors waited for more clarity on U.S.-China trade talks. At 1415 GMT, the rand traded at 17.69 against the dollar , about 0.2% stronger than Monday's closing level. South Africa's manufacturing output (ZAMAN=ECI), opens new tab fell 6.3% year on year in April, the sixth consecutive monthly decline, statistics agency data showed on Tuesday. Analysts polled by Reuters had expected a drop of 3.9%. Weakness in the manufacturing sector was one factor behind the first quarter's sluggish growth of just 0.1%(ZAGDPN=ECI), opens new tab, offsetting a strong performance by agriculture. The rand was also supported on Tuesday by a stronger global gold price and by a weaker U.S. dollar . The Johannesburg Stock Exchange's Top-40 index (.JTOPI), opens new tab was last up 0.6%. The benchmark 2035 government bond was stronger, as the yield fell 4 basis points to 10.095%.
Reuters
3 hours ago
- Reuters
Kenya central bank cuts main lending rate to 9.75%
NAIROBI, June 10 (Reuters) - Kenya's central bank cut its benchmark lending rate (KECBIR=ECI), opens new tab to 9.75% on Tuesday from 10.00% previously, the bank's Monetary Policy Committee said. It was the sixth monetary policy meeting in a row that the Central Bank of Kenya has lowered the rate. "There was scope for a further easing of the monetary policy stance to augment the previous policy actions aimed at stimulating lending by banks to the private sector and supporting economic activity," the bank said in a statement. Economists polled by Reuters had been divided on what the central bank's decision would be. Out of seven forecasts three were for a cut, three for no change in the policy rate and one for a hike.
Reuters
3 hours ago
- Reuters
Modest UK economic growth to lead Bank of England to cut rates gradually: Reuters poll
BENGALURU, June 10 (Reuters) - The British economy will grow a mild 1% this year with the Bank of England set to cut interest rates two more times in 2025, according to economists polled by Reuters, little changed from previous projections despite tariff uncertainty. The survey was completed before finance minister Rachel Reeves' planned comprehensive spending review on June 11, with the biggest increases expected to focus on health and defence. Median expectations in the June 5-10 poll of 52 economists showed the economy growing 1.0% this year - a view largely unchanged since February - and accelerating slightly next year to 1.2%. That compares with a 1.1% expansion in 2024. Poll forecasts match the Office for Budget Responsibility's latest projections. The UK economy grew 0.7% in the first quarter, topping expectations, but growth is expected to slow to 0.1% this quarter and 0.2% in the third quarter, followed by a 0.3% rise in the final three months of 2025. "Fundamentally we haven't changed our growth forecast for 2025 for the past few months because tariffs won't have a huge impact on the economy. The car industry, steel, pharmaceuticals are in the firing line but as a proportion of GDP, UK goods exports to the U.S. are only about 2%," said James Smith, economist at ING. Britain is the only major economy to have agreed a trade deal with the U.S., exempting it from President Donald Trump's increased tariffs on steel and aluminium imports for now, but a 10% goods levy remains in place. The Bank of England is forecast to keep its Bank Rate on hold at 4.25% next week, followed by a likely one quarter-point rate cut in August and another in the final three months of the year to 3.75%, according to a large majority of the 59 economists polled. Markets are also pricing in two further rate cuts this year after official data on Tuesday showed a slight rise in the jobless rate and a slowdown in wage inflation. The central bank's Monetary Policy Committee may be more confident now about sticking to its gradual easing path, economists said. "Today's weak jobs and slower pay growth may tip the balance in favour of an August cut," noted Elizabeth Martins, senior UK economist at HSBC. "Certainly, market pricing for such an outcome has increased." Overall, inflation was expected to remain elevated at an average 3.4% this quarter and 3.3% the next, before easing below 3.0% early next year, poll medians showed. (Other stories from the Reuters global economic poll)
